Natixis Advisors, L.P. Cytokinetics Inc Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 18,473 shares of CYTK stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,473
Previous 45,465
59.37%
Holding current value
$1.12 Million
Previous $1.83 Million
66.61%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CYTK
# of Institutions
371Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.07 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$892 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$729 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$476 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$388 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.73B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...